letermovir: Clinical Trials

13 trials of letermovir, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 5 recruiting, 1 active not recruiting, 1 unknown. 13 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 313Completed 6, Recruiting 5, Active not recruiting 1, Unknown 1
Phase 21Recruiting 1

Follow letermovir: new trials by email Literature Review of letermovir trials Research Report on letermovir

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant
Letermovir, Valganciclovir - CMV Viremia, Heart Transplant Infection
Phase 2 / Phase 3RecruitingColumbia University1502025-09-122026-10-02
Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections
Letermovir, Valganciclovir, Letermovir placebo - Cytomegalovirus Infection
Phase 3RecruitingAssistance Publique - Hôpitaux de Paris802024-08-142026-01-02
Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients
Letermovir - Cytomegalovirus Infections, Kidney Transplant Infection
Phase 3RecruitingUniversity of Wisconsin, Madison902024-08-082026-06-11
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
Biospecimen Collection, Letermovir - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Phase 3RecruitingChildren's Oncology Group1052024-07-112026-10-06
CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT
Letermovir - Hematologic Malignancy
Phase 3Active not recruitingRuijin Hospital2502024-07-012025-12-15
Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus Infection
Letermovir 480 MG, Ganciclovir - CMV Infection
Phase 3UnknownHospital do Rim e Hipertensão1002024-05-052024-04-02
Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Versus Valaciclovir
Letermovir, Valacyclovir - Pregnant Women, CMV Infected Fetuses
Phase 3RecruitingAssistance Publique - Hôpitaux de Paris462023-10-202026-03-31
De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients
Letermovir 480 mg once daily, Historical/Control - Kidney Transplant; Complications, CMV
Phase 3CompletedVirginia Commonwealth University302023-09-252026-09-23
A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045)
Letermovir - Cytomegalovirus Infection
Phase 3CompletedMerck Sharp & Dohme LLC1202023-03-242025-03-25
MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)
Letermovir tablet, Letermovir IV - Cytomegalovirus Infection, Cytomegalovirus Disease
Phase 3CompletedMerck Sharp & Dohme LLC222019-12-272024-08-21
Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)
Letermovir, Placebo - Cytomegalovirus Infection
Phase 3CompletedMerck Sharp & Dohme LLC2202019-06-212024-08-22
Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)
Letermovir, Valganciclovir, Acyclovir (ACV) - CMV Disease
Phase 3CompletedMerck Sharp & Dohme LLC6012018-05-032023-07-28
Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)
Letermovir, Placebo - Prevention of CMV Infection or Disease
Phase 3CompletedMerck Sharp & Dohme LLC5702014-06-062019-09-11

Conditions studied

Cytomegalovirus Infections (6)  ·  Hematologic Neoplasms (2)  ·  Disease (1)  ·  Rejection, Psychology (1)

Sponsors

Merck Sharp & Dohme LLC (5)  ·  Assistance Publique - Hôpitaux de Paris (2)  ·  Children's Oncology Group (1)  ·  Columbia University (1)  ·  Hospital do Rim e Hipertensão (1)  ·  Ruijin Hospital (1)  ·  University of Wisconsin, Madison (1)  ·  Virginia Commonwealth University (1)

Countries

United States (6)  ·  France (4)  ·  China (2)  ·  Germany (2)  ·  Italy (2)  ·  Japan (2)  ·  United Kingdom (2)  ·  Argentina (1)  ·  Australia (1)  ·  Austria (1)  ·  Belgium (1)  ·  Canada (1)  ·  Colombia (1)  ·  Hungary (1)  ·  Mexico (1)

Top investigators

Caitlin W Elgarten (1)  ·  Gaurav Gupta, MD (1)  ·  Helio Tedesco (1)  ·  Sandesh Parajuli, MBBS (1)

Results publications

PMID 27682069, PMID 29211658, PMID 29319768, PMID 30137245, PMID 31081566, PMID 31179485, PMID 31978003, PMID 32134486, PMID 33440077, PMID 34674258, PMID 36464218, PMID 37279999, PMID 38142695, PMID 38615067, PMID 38700045, PMID 38853607, PMID 41321121, PMID 42639594

NIH funding

2017 (1), 2018 (1), 2023 (1), U24CA196173 (1), UG1CA189955 (1)